Drugs / Retinoic acid
Trials 10
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 03 trials | ||||||
| Phase 0 | NCT05281965 | Apr 2022 → Jun 2023 | 15q11q13 microduplication syndrome, autism spectrum disorder | Second Affiliated Hospital, School of Medicine, Zhejiang University | Unknown | No outcome recorded |
| Phase 0 | NCT03491267 | Jan 2018 → Nov 2024 | central centrifugal cicatricial alopecia | Johns Hopkins University | Completed | No outcome recorded |
| Phase 0 | NCT03392623 | Jan 2015 → Jan 2016 | hyperpigmentation of the skin | Autonomous University of San Luis Potosí | Completed | No outcome recorded |
| Phase 11 trial | ||||||
| Phase 1 | NCT00533169 | Sep 2007 → Feb 2011 | neuroblastoma | M.D. Anderson Cancer Center | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT07015931 | Nov 2024 → Mar 2025 | acne | Indonesia University | Completed | No outcome recorded |
| Phase 1/2 | NCT06020833 | Aug 2023 → Oct 2025 | myelodysplastic syndrome | Peking Union Medical College Hospital | Withdrawn | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT06731140 | Feb 2025 → Oct 2026 expected | Her2-receptor negative breast cancer | Fudan University | Recruiting | No outcome recorded |
| Phase 2 | NCT01048086 | Jun 2009 → Nov 2013 | neuroblastoma, neuroendocrine neoplasm | University of Iowa | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT00339196 | Jul 2006 → Jul 2008 | acute myeloid leukemia, myelodysplastic syndrome | Assistance Publique - Hôpitaux de Paris | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT04175587 | Dec 2019 → Aug 2021 | acute promyelocytic leukemia | Peking University People's Hospital | Unknown | No outcome recorded |
| Comparator or background therapy5 trials | ||||||
| Phase 2 | NCT05119413 Background | Nov 2021 → Sep 2022 | hyperpigmentation of the skin | Centre Hospitalier Universitaire de Nice | Completed | Missed primary |
| Phase 2 | NCT02641782 Background | Nov 2015 → Dec 2016 | neuroblastoma | University of Cologne | Terminated | No outcome recorded |
| Phase 4 | NCT07676994 Comparator | May → Dec 2025 | hyperpigmentation of the skin | Ghurki Trust and Teaching Hospital | Completed | No outcome recorded |
| Phase 4 | NCT00863278 Comparator | Mar 2009 → Mar 2010 | hyperpigmentation of the skin | Centre Hospitalier Universitaire de Nice | Terminated | No outcome recorded |
| — | NCT04417348 Comparator | Jan → Sep 2019 | hyperpigmentation of the skin | Autonomous University of San Luis Potosí | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 15 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Retinoic Acid | “BACKGROUND: Kligman's trio (KT), combining hydroquinone, retinoic acid and corticosteroid, is considered as the gold standard treatment of melasma.” PMID 37620285 ↗ Sep 202315“New trio combination is a drug containing 0.1% isobutylamido-thiazolyl-resorcinol, 0.1% retinoic acid and 0.1% dexamethasone” NCT07676994 ↗ “5-azacytidine (Vidaza®) + Valproic Acid (Depakine ®) Before Administration of Retinoic Acid (Vesanoid®)” NCT00339196 ↗ “The combination of hydroquinone, retinoic acid and steroids combined in topical daily application.” NCT00863278 ↗ |
| Known as | Vesanoid | “5-azacytidine (Vidaza®) + Valproic Acid (Depakine ®) Before Administration of Retinoic Acid (Vesanoid®)” NCT00339196 ↗ |
| Action | Activate | “They act through binding to and activating specific nuclear receptors” NCT00339196 ↗ |
| Modality | Small molecule | “Retinoids represent a large group of compounds structurally related to vitamin A (retinol)” NCT00339196 ↗ |
| Route | Oral | “by mouth” NCT00533169 ↗ |